Alison M. Weppler

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study

Inês Pires da Silva, Tasnia Ahmed, Irene L. M. Reijers et al. · The Lancet Oncology · 2021 · 201 citations

Oncology, Anti-pd-1 Therapy, Melanoma +10

Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders

Lauren Brown, Alison M. Weppler, Prachi Bhave et al. · Journal for ImmunoTherapy of Cancer · 2021 · 88 citations · Full text

Immunodeficiencies, Immunology, Immunoediting +25

Hematological immune related adverse events after treatment with immune checkpoint inhibitors

Rafaela Kramer, Anne Zaremba, Alvaro Moreira et al. · European Journal of Cancer · 2021 · 84 citations

Hematological Malignancy, Autoimmune Disease, Immune Checkpoint Inhibitors +8

Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors

Jenny Lee, Alexander M. Menzies, Matteo S. Carlino et al. · Clinical Cancer Research · 2020 · 78 citations · Full text

FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment

Amir Iravani, Medhat Osman, Alison M. Weppler et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2020 · 63 citations

Oncologic Imaging, Medicine, Melanoma +10